.
The data collection of adverse events of anti-HIV drugs (D:A:D)
collaborative cohort study has analysed data from over 33,000 patients (D:A:D Study Group et al., 2008) . D:A:D analyses highlight an increased relative rate of MI that is associated with exposure to ART (Friis-Moller, Sabin, et al., 2003) . Furthermore, recent use of the NRTI ABC was associated with a 90% increase in the relative rate of MI (D:A:D Study Group et al., 2008) . ABC-associated risk persisted in a follow-up study, despite a channelling bias away from ABC in PLWH who presented with a higher cardiovascular risk profile (Sabin et al., 2016) . Incident cardiovascular risk was also associated with ABC but not TDF in later cohort studies (Choi et al., 2011; A:D Study Group et al., 2008) . Subsequent studies have confirmed the link between ABC and MI whereas, in contrast, others have not (see Alvarez, Orden, et al., 2017) . A FDA-led meta-analysis did not find an association between ABC and MI (Ding et al., 2012) , so that a consistent link between ABC and cardiovascular risk in PLWH has not been established.
As MI is platelet-driven, several studies have investigated the effects of ART on platelet function. Clinical studies have reported enhanced ex vivo platelet aggregation in PLWH compared with matched HIV-negative controls (Satchell et al., 2010) . Furthermore, ABC was associated with enhanced platelet aggregation compared to patients on alternative therapies (Satchell et al., 2011) , including TDF, which had no effect (Munoz et al., 2012) . There are contrasting reports demonstrating that ABC has no effect on platelet activation in response to ADP and collagen (Alvarez, Rios-Navarro, et al., 2017; Diallo et al., 2016) . Indeed, Alvarez, Rios-Navarro, et al. (2017) proposed that ABC-mediated enhancement of thrombosis is via a direct interaction of the drug with the vascular endothelium. Direct comparison between these studies is complicated by differences in HIV-associated factors, lifestyle, biological, and medical characteristics of participants and parameters assessed. Thus, a pharmacological link between ABC and enhanced platelet activation has not been shown and remains hypothetical. We have therefore assessed the comparative pharmacological effects of the alternative ART backbone therapies ABC, TDF, and the newer tenofovir (TFV)-based compound TAF on platelet activation, independently of confounding factors associated with HIV infection by recruiting HIV-negative volunteers for in vitro and ex vivo studies, and in vivo using inbred mouse strains.
| METHODS

| Human platelet preparation
This study was approved by the Imperial College London Research Ethics Committee and informed consent was obtained from healthy, HIV-negative volunteers, in accordance with the Declaration of Helsinki. Volunteers, male and female, had not taken aspirin, steroids, antihistamines or used an inhaler or an investigational product within the last 6 months; they were also non-smoker. Volunteers confirmed that they had not recently taken NSAIDs or SSRIs or suffered from a chronic condition such as diabetes. Blood was collected in acid citrate dextrose (9:1) and PRP was collected following centrifugation (175× g, 15 min). Where indicated, PRP was washed twice (1400× g, 10 min, 2 μM PGE 1 ) and platelets were resuspended in a modified Tyrode'sHEPEs buffer (134-mM NaCl, 2.9-mM KCl, 20-mM HEPES, 4.5-mM glucose, 12-mM NaHCO 3 , 0.34-mM Na 2 HPO 4 , and 1-mM MgCl 2 ) and rested for 30 min prior to use.
| Microplate aggregation assay
Platelet suspensions were preincubated with NRTIs or vehicle control, as indicated, for 30 min at 37°C. Platelets were added to a 96-well
What is already known
• Cardiovascular risk is elevated in people living with HIV and hypothesized to be exacerbated by certain antiretrovirals.
What this study adds
• Mechanistic insights demonstrating differential effects of antiretrovirals upon platelet activation.
What is the clinical significance
• Our data could ultimately lead to improved management of multimorbidity in people living with HIV.
plate (VWR, Leicestershire, UK) containing agonists, and the plate was read at 20-s intervals for 16 min in a Power Wave X5 plate reader (Bio-TEK, Swindon, UK). The machine was maintained at 37°C for the duration of the experiment with shaking for 7 s before each reading. Maximum aggregation at 16 min was calculated as a percentage change in absorbance, compared to baseline.
| Light transmission aggregometry
For selected experiments, platelet aggregation was monitored in a Model 400 aggregometer (Chrono-Log, Labmedics, Abingdon, UK) as described previously (Jones et al., 2010) .
| Flow cytometry
Kinetic flow cytometry was performed using methodology described previously (Jones et al., 2014) 
| Animals
All animal care and experimental procedures were approved by the Imperial College London Animal Welfare and Ethical Review Board, and appropriate licences were obtained from the UK Home Office.
Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) 
| In vivo platelet aggregation
In vivo platelet aggregation was assessed in real time as the thromboembolic accumulation of In 111 -radiolabelled (Mallinckrodt Pharmaceuticals, Surrey, UK) mouse platelets in the pulmonary region of anaesthetized (25% urethane; 10 μl·g −1 ; Sigma-Aldrich; Dorset, UK) mice via an external scintillation probe as described previously (Tymvios et al., 2008) . Animals were randomized to treatment groups. To account for the higher metabolic rate of mice compared with humans, NRTI doses were administered to achieve 10× the human C max levels such that mice were given a single i.p. 
| Ex vivo platelet aggregation
Regulatory and ethical approvals were obtained before initiating the study. Subjects signed written informed consent prior to being enrolled in the study. The study was registered at ClinicalTrials.gov 
| Data and statistical analysis
The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology. Data were analysed in GraphPad Prism (v7.04, RRID:
SCR_002798, California, USA), presented as the mean ± SEM, and statistical significance was determined using a two-way ANOVA or paired students' t-test with two tails, as appropriate and indicated in the independent experiments for each condition. *P < 0.05, significantly different from vehicle; two-way ANOVA were supplied by Gilead Sciences (California, USA). Type 1 collagen from bovine tendon was from Takeda (Osaka, Japan). Unless stated, all other reagents were from Sigma-Aldrich.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
3 | RESULTS
| NRTIs do not affect platelet aggregation in vitro
We adopted a medium-throughput microplate-based approach to enable simultaneous evaluation of the effects of NRTIs on platelet aggregation to ADP, collagen, and TRAP6. Platelets were preincubated with plasma concentrations that correspond to C max (i.e., 3 μg·ml Because acute in vitro exposure to drugs may poorly model patients on chronic ART, we exposed platelets to 30-100× plasma NRTI C max and did not observe any significant effect of ABC, TAF, TDF, or TFV on platelet aggregation responses ( Figure S2 ). Figure 1b shows that incubation of PRP with TFV (0.05 μM) significantly reduced the 3-μM TRAP6-induced aggregation response by 21.0 ± 8.7% (Figure 1bC ). This inhibitory effect was not seen at other agonist concentrations, in studies using washed platelets or following exposure of platelets to a broad range of TFV concentrations (0.01-30 μM; Figure S2d ). Similar data were obtained using conventional aggregometry where platelets were pretreated with C max levels of ABC, TAF, or TDF and stimulated by 10 μg·ml −1 collagen for 3 min ( Figure S3 ).
| Abacavir enhances human platelet granule release
Having generated no evidence of increased platelet aggregation by any of the studied NRTIs, including ABC, using an end-point assay,
we progressed to kinetic flow cytometry to evaluate real-time Data are representative of six independent experiments. *P < 0.05, significantly different from vehicle; two-way ANOVA preincubation did not alter collagen-induced CD62P or CD63 expression (Figure 2a-b) . Collagen-induced PAC-1 binding was not affected by any NRTI, including ABC (Figure 2c ). Our observations regarding the effects of ABC on granule secretion were specific to collagen, as neither ADP nor TRAP6 had a significant effect on CD62P, CD63, or PAC-1 binding ( Figure S4 ).
| Abacavir metabolite interrupts NO-mediated inhibition of platelet aggregation
The active anabolite of ABC, CBV-TP, is a guanosine analogue and antagonism of NO-cGMP-mediated inhibitory pathways in the platelet has been suggested as a potential mechanism by which ABC may affect platelet function (Baum, Sullam, Stoddart, & McCune, 2011) .
We hypothesized that CBV-TP would interrupt NO-mediated inhibition of aggregation whereas TFV, an adenosine analogue, would not.
The NO donor SNAP significantly reduced ADP-induced platelet aggregation by 37.3 ± 6.9% (Figure 3a) . Inhibition was significantly reversed upon application of the soluble guanylate cyclase inhibitor ODQ ( Figure 3a ) and also by CBV-TP. Parallel experiments were conducted in the presence of TFV, the active anabolite of both TAF and TDF. TFV-treated platelets remained susceptible to SNAP-mediated inhibition and were not significantly different to SNAP in the presence of vehicle control (Figure 3b ). We wished to confirm that the effect of ABC was specific to the NO/cGMP axis and evaluate the effect of TFV, an adenosine analogue, upon adenylate cyclase/cAMP signalling.
Preincubation with the adenylate cyclase activator, forskolin, reduced ADP-evoked aggregation from 36.6 ± 6.7% to 6.0 ± 4.0% (Figure 3c ; Taken together, these data support the hypothesis that CBV-TP, but not TFV, is able to selectively interrupt NO-mediated inhibition of platelet aggregation. This effect was independent of adenylate cyclase activity. To investigate the physiological relevance of this finding in the context of endothelial generation of NO, we employed an in vivo mouse model of platelet aggregation in which radiolabelled platelets freely circulate and upon i.v. injection of a platelet agonist, aggregate and become trapped in the pulmonary vasculature (Tymvios et al., 2008) . Dynamic platelet aggregation can be determined in real time via an external scintillation probe suspended over the pulmonary region. Platelet aggregation in this model has previously been shown to be highly sensitive to inhibition of endogenous NO production (Moore, Tymvios, & Emerson, 2010) .
Collagen elicited a rapid accumulation of radiolabelled platelets in the thoracic region of vehicle (DMSO) control mice that resolved over time (Figure 4 ). In the presence of ABC, aggregation responses achieved a greater peak and took longer than vehicle control to resolve, which was reflected in a higher AUC (Figure 4a ). Conversely, exposure of mice to TDF did not alter the peak aggregation response or AUC compared to vehicle-treated mice (Figure 4b ).
Due to elevated levels of plasma esterase activity in mice compared to humans, TAF is not stable in wild-type mice and is rapidly degraded. The physiological effect of TAF on platelet activation was therefore assessed in Ces1c −/− mice, in which TAF has been shown to be stable. Ces1c −/− mice were treated with TAF or vehicle (DMSO)
for 30 min prior to injection of collagen. Peak aggregation responses and AUC were not significantly different between groups. Thus, ABC increased collagen-induced platelet aggregation in vivo whereas TDF and TAF had no effect.
| TFV-based therapies do not alter platelet activation at clinically relevant dosing
Clinical studies comparing the effects of ABC and TDF on platelet to TDF and an improved kidney and bone safety profile (Post et al., 2017) . There is early evidence to suggest that TAF may have comparable efficacy to TDF in PrEP formulations (Massud et al., 2016) . However, in contrast to ABC and TDF, the effects of TAF/FTC on platelet function have not been assessed in a clinically relevant setting. In the context of a Phase I clinical trial, we determined the effects of daily TAF/FTC, relative to TDF, administration upon platelet aggregation and activation. Platelet analyses were conducted predose on Day 1 (baseline) and postdose after achieving steady-state plasma NRTI levels (28 days). Platelet aggregation was determined in response to increasing concentrations of ADP, collagen, and TRAP6. Intrasubject analyses did not reveal any change in maximum aggregation responses between baseline and TAF/FTC-or TDF-treated samples (Figure 5a-c) .
Flow cytometric analysis of platelet activation markers was conducted in a subgroup of four (20%) subjects enrolled on the trial. These exploratory studies assessed integrin α IIb β3 activation (Figure 5d ) and granule release (Figure 5e -f) in response to ADP, collagen, and TRAP6. We did not observe any apparent effect of TAF/FTC or TDF on integrin action (Figure 5d ), α (Figure 5e ), or dense granule (Figure 5f ) release.
| DISCUSSION
HIV treatment has led to dramatic improvements in health so that PLWH no longer progress to AIDS. The major cause of death in PLWH is CVD (D:A:D Study Group et al., 2008; Islam et al., 2012) , which is the same as the general population. Several studies, however, have linked both HIV and ART with increased risk of platelet-driven cardiovascular events, principally MI (Friis-Moller, Sabin, et al., 2003; Pollack & Rind, 2007; Sabin et al., 2016; Satchell et al., 2010; Satchell et al., 2011) . It has also been suggested that ABC may be specifically associated with increased cardiovascular risk but there is no consensus on this topic. Cohort and observational studies demonstrating a link between ART and MI or platelet aggregation are limited by confounding factors, for example, impaired kidney function is both a contraindication for TDF use and a cardiovascular risk factor (Sax et al., 2015) . In addition, a meta-analysis did not reveal any additional effect of ABC in relation to CVD (Ding et al., 2012) so that existing data are conflicting. EACS guidelines stipulate that patients with a high cardiovascular risk profile (>20%) are now channelled away from ABC (EACS, 2017) so that matching cohorts is increasingly challenging. To test the hypothesis that ABC drives cardiovascular risk by pharmacologically enhancing platelet aggregation, we designed a study to compare the effects of ABC-and TFV-based therapies, independent of major confounding factors (e.g., HIVassociated factors and previous ART use).
We first demonstrated that incubation of platelets from HIV negative, healthy volunteers with NRTIs had no effect on subsequent platelet aggregation. We adopted a 96-well format to allow simulta- collagen was injected (arrows), and responses were monitored for 10 min. ABC and TDF experiments were conducted using wild-type (WT) C57bl/6 mice, whilst Ces1c −/− mice were utilized for TAF. The AUC was calculated for the duration of the experiment and representative traces and summary data are shown. Data are representative of seven independent experiments. *P < 0.05, significantly different from vehicle; paired, two tailed Students' t-test in vitro also standardized drug exposure by avoiding pharmacokinetic variability. It is not possible to conclude definitively from these studies that NRTIs had no effects on platelet aggregation as our data are limited by the use of an end-point, rather than a real-time, assay.
We did however additionally perform gold-standard aggregometry experiments in cuvettes and found no effect of any NRTIs used in this study ( Figure S3 ). In addition, although we used clinically relevant C max concentrations of NRTIs, the extent to which these modelled chronic exposure of drugs in patients is unclear given that (Massud et al., 2016) .
We employed flow cytometry to dynamically quantify the effects of NRTIs on platelet activation. We found that, in contrast to TAF and TDF, ABC exposure enhanced collagen-evoked dense and α granule release but had no effect on granule release when platelets were stimulated by other agonists. An alternative approach to the in vitro studies reported here, is the use of switch studies in which PLWH are randomized to switch from ABC to TFV-based therapies. Results from these studies are now emerging and have shown persistently lower collagen-induced platelet aggregation in patients switching to TAF, compared with those remaining on ABC .
Other agonists either had no effect or only a transient effect.
Together, these data suggest an effect of ABC on the rate of collagen-induced granule secretion that could lead to enhanced platelet aggregation in a patient setting. This finding requires further exploration but could potentially be explained by differential sensitivities of collagen-compared to ADP-or TRAP6-evoked granule release, cGMP-mediated inhibition or a direct effect of ABC on collagenevoked platelet granule release. Given that our flow cytometry experiments were conducted in isolated platelets and therefore in the and four (d-f) subjects enrolled on the trial. In (a-c), no significant effects; two-way ANOVA absence of NOS, which is not expressed in platelets (Tymvios et al., 2009) , it is possible that ABC directly effects granule release independently of NO/cGMP ( Figure 6 ). An overarching involvement of NO/cGMP cannot be completely excluded however, as bioactive NO has been shown to be generated in platelets via reduction of inorganic nitrite (Apostoli, Solomon, Smallwood, Winyard, & Emerson, 2014 ).
Thus, it is possible that ABC may alter platelet activation and influence thrombus formation through multiple pathways.
Previous studies have highlighted that CBV-TP, the active metabolite of ABC, may, as a guanosine analogue, competitively inhibit NO-cGMP-mediated signalling (Baum et al., 2011) . As NO is a major negative regulator of platelet activation, this provides a potential mechanism by which ABC could drive cardiovascular risk and act differently to TFV. We adopted two approaches. Firstly, we employed in vitro aggregometry and, since platelets do not express NOS enzymes (Tymvios et al., 2009) , applied NO exogenously via SNAP.
Secondly, we used an in vivo mouse model in which platelets circulate in the context of a functional vascular endothelium (Tymvios et al., 2008) . Critically, this model has been shown to be extremely sensitive to pharmacological inhibition of endogenous NOS Moore, Sanz-Rosa, & Emerson, 2011) . These complementary approaches provided further evidence that CBV-TP, but not TFV, could block NO-mediated inhibition of platelet aggregation and that ABC, but neither TDF nor TAF, led to enhanced platelet aggregation in vivo. Given the central role of the endothelium in generating NO and the potential effect on NO-mediated platelet inhibition, these data suggest that ABC exposure may be problematic in the context of endothelial dysfunction, which is in line with current clinical guidelines that ABC should be used with caution in patients with elevated cardiovascular risk (EACS, 2017) . The endothelium also generates prostacyclin, which inhibits platelet activation through induction of the adenylate cyclase/cAMP axis (Schwarz, Walter, & Eigenthaler, 2001) . We found that NRTIs did not affect this pathway but, rather, selectively affect the NO/cGMP axis ( Figure 3c ). Our proposed model for ABC-mediated cardiovascular risk is summarized in Figure 6 .
In summary, the data presented here provide evidence that ABC can pharmacologically alter platelet function in vitro and in vivo, whereas the TFV-based therapies TDF and TAF had no effect. These observa- 
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